IDIBELL on the media
IDIBELL and Bellvitge Hospital lead a study on the effectiveness of icatibant against COVID-19
Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital had launched a clinical study, along with the pharmaceutical company Takeda, to evaluate the efficacy and safety of Icatibant as a treatment against COVID-19.
Identified the genetic mechanisms for the acquisition of resistance to antibiotics in H. parainfluenzae
The work of the Epidemiology of Bacterial Infections research group of IDIBELL and HUB indicates that the bacteria could achieve the resistance through the acquisition of mobile DNA fragments.
IDIBELL celebrates the Kickoff Meeting on Health Research Projects awarded by ISCIII
Last Tuesday, April 20th, within the Areté Training Program, the IDIBELL AES-2020 Kick Off Meeting was held, aimed at all researchers who have obtained a health research project within the “2020 AES Call” funded by the ISCIII.
Confirmed the presence of autoantibodies against type 1 interferon as an indicator of COVID-19 poor prognosis
A study led by IDIBELL and the Infanta Eleonor University Hospital in Madrid shows that 10% of patients with severe COVID-19 present neutralizing antibodies against the cytokine interferon type 1.
Discovery of Epigenetic Factors. Predicting the Severity of COVID-19
We found that there were epigenetic variations, the chemical switches that regulate DNA activity, in the individuals positive for the virus who developed a severe COVID-19.
Created the largest public database of genetic variants that regulate the expression of genes in the colon to date
The study has also permitted identify genetic variants that modify the expression of genes in the colon and that are associated with diseases such as colorectal cancer, but also with other organs such as the brain, showing the relationship between the intestine and the brain.
Voice analysis with artificial intelligence models may allow early detection of bulbar involvement in ALS
An investigation by the International Center for Numerical Methods in Engineering (CIMNE) and the University of Lleida (UdL), in which IDIBELL and the Hospital de Bellvitge has participated, has developed automated voice markers to identify early affectations of the disease.
IDIBELL researchers define a new mechanism of aging in a bone marrow stem cell in women
To equilibrate the gene expression between XX females and XY males, one of female X chromosomes is inactivated. Researchers from IDIBELL Regenerative Program has discovered that this inactivation is affected in bone marrow aged stem cells.
Years of disease have a decisive impact on the response to the treatment of eating disorders (ED)
A study by IDIBELL and Bellvitge Hospital establishes, for the first time, a temporary criterion for the risk of chronicity of symptoms for the different subtypes of ED.
Researchers define the clinical characteristics of the cerebral complications caused by oncological immunotherapies that determine the evolution
The study describes two syndromes, which combine clinical manifestations and differential cerebrospinal fluid profiles, which determine a different prognosis in patients.